International Council for Harmonisation (ICH) E6 Practice Exam

These questions are part of the practice quiz. Start practicing

• What is a key consideration when including information about alternative treatments in consent forms?
• What does ICH E2A specifically address?
• What does ICH E6 Section 4.8.10(e) require regarding the subject's responsibilities?
• What is one key aspect of the sponsor's monitoring responsibility?
• According to ICH E6, what should be implemented when noncompliance is identified?
• What is the key responsibility of the trial monitor during a clinical trial?
• According to ICH E6, how long must essential documents be retained by the sponsor?
• In what circumstances can the informed consent process be waived according to ICH E6?
• Which organization does not require assent from incompetent subjects, while ICH does?
• Which entities does the ICH E6 guideline apply to?
• How long does a sponsor need to retain records according to FDA regulations for investigational drugs?
• The main purpose of ICH is to facilitate which of the following?
• What is the primary requirement related to medical care of trial subjects according to ICH E6?
• What does the term "site initiation" refer to in a clinical trial?
• Who must have access to trial-related records upon request?
• What must be explained in the consent form regarding alternative treatments?
• Which of the following is a requirement for waiving informed consent for minimal risk research according to FDA guidance?
• According to ICH E6, what information must be included about the probability of assignment in a study?
• Who is primarily responsible for ensuring compliance with ICH E6 guidelines during clinical trials?
• Which of the following roles has direct access to subject medical records under ICH E6 requirements?
• During a clinical trial, the investigator must ensure which of the following?
• What does ICH E6 require the sponsor to verify regarding subject consent?
• What is the purpose of monitoring in clinical trials according to ICH E6?
• In the context of ICH E6, what does GCP stand for?
• Which best describes the responsibilities for adverse event reporting?
• In emergency situations, if prior consent is not possible, what should happen according to ICH guidelines?
• What role does a Data Safety Monitoring Board (DSMB) play in clinical trials?
• What is a key principle centered around participant safety in clinical trials?
• What does the term 'participant confidentiality' emphasize in clinical trials?
• What is required by ICH E6 Section 5.18.6 regarding monitoring results?
• What can enhance the quality of a post-study evaluation?
• Why is it important to maintain confidentiality of trial participants?
• Which of the following is true regarding changes in research protocols under FDA regulations?
• ICH E6 serves as the international standard for which aspect of clinical research?
• What must be true for conducting non-therapeutic trials with legally acceptable representatives?
• What is required by ICH E6 guidelines for a subject prior to participation in a trial?
• What role does the Institutional Review Board (IRB) play in clinical trials?
• Which of the following is NOT a member of the ICH as listed?
• True or False: ICH E6 allows broader access to research records than FDA regulations.
• What is the primary goal of ICH E6 in clinical research?
• What is the Clinical Study Report (CSR) primarily used for in clinical trials?
• Which responsibility falls under the sponsor's domain according to ICH E6?
• In the case of a global marketing application, records must be kept for how long after the last regulatory agency approval?
• Under what circumstance must the sponsor conduct a root cause analysis according to ICH E6?
• What must an investigator do if they expect illiterate subjects to enroll in studies often?
• What should be weighed before initiating a clinical trial?
• What type of insights do participants provide regarding clinical trials?
• According to ICH (2016) Section 4.8.10(n), informed consent must indicate access to what?
• What requirement is stated for FDA-regulated drug studies regarding ICH E6 compliance?
• If a subject is illiterate, what does ICH recommend?
• What is the main benefit of adhering to Good Clinical Practice?
• What is the significance of "source data" in ICH E6?
• Why is continuous risk assessment necessary throughout a clinical trial?
• What must be reviewed by the IRB/IEC regarding payments to research subjects?
• Which section of ICH E6 addresses the responsibilities of the investigator?
• What type of approach does ICH E6 Section 5.0 recommend for quality management in trials?
• What action should be taken if a clinical trial encounters unexpected adverse events?
• What is a primary purpose of the International Council for Harmonisation (ICH)?
• What is the purpose of the Case Report Form (CRF) in ICH E6?
• What is one responsibility of the IRB according to ICH guidelines?
• What are "essential documents" as defined by ICH E6?
• What aspect is not specifically addressed by FDA regulations according to ICH E6?
• Which category is NOT one of the main categories of ICH guidelines?
• What should be included in the Investigator’s Brochure (IB)?
• What does the term "blind" refer to in clinical trials?
• What aspect is crucial for the conduct of clinical trials according to ICH guidelines?
• What is required by ICH E6 if there is no intended clinical benefit to the subject?
• What does the term "audit" refer to in the context of ICH E6?
• According to ICH E6, how is a clinical trial defined?
• How can compliance with ICH E6 be ensured during remote monitoring?
• Why is training important for clinical trial personnel according to ICH E6?
• How is risk management addressed in ICH E6 for clinical trials?
• What is the consequence of failing to comply with protocol during a clinical trial?
• What must the IRB consider when evaluating a waiver of consent for minimal risk research?
• What role does the IRB/IEC play in emergency consent situations?
• Which best describes the role of essential documents in ICH E6 Section 8.1?
• What is an investigator's responsibility regarding protocol amendments?
• Who can be a Legally Authorized Representative (LAR) in a clinical trial?
• In the U.S., how does the FDA treat ICH E6?
• What does ICH require regarding statements about subjects' responsibilities?
• What is vital for ensuring participant safety during a clinical trial?
• What document primarily allows the IRB to evaluate the trial?
• For non-therapeutic trials, according to ICH E6, who must give consent?
• How many parts are there in the ICH E6 guideline?
• Which of the following best describes ICH GCP principles?
• Which criteria is essential for selecting a clinical trial site?
• What aspect of clinical research does the ICH GCP guidelines specifically address?
• What is the importance of protocol compliance in clinical trials?
• The ICH E6 guideline primarily serves which type of entities in global research?
• Under what condition can deviations from the trial protocol occur without prior IRB approval?
• Which of the following is NOT a component of the ICH E6 guideline?
• According to FDA regulations, what specific document must an IRB keep copies of?
• In ICH guidelines, what is pivotal for protecting the rights of trial subjects?
• What criteria does ICH E6 suggest for selecting clinical trial investigators?
• What is the role of the FDA regarding ICH E6 guidelines?
• What is the primary goal of the International Council for Harmonisation (ICH)?
• Which document provides essential information for the clinical trial protocol according to ICH E6?
• What must be included in the informed consent form according to FDA regulations?
• How does the ICH guideline relate to redundant research?
• To comply with ICH guidelines, what should be included in the consent form?
• Which responsibilities are NOT included for investigators under ICH E6?
• What ethical considerations are paramount according to ICH E6?
• Which area does the ICH E6 guideline NOT replace according to its definition?
• Which of the following is NOT a requirement for essential documents in ICH E6?
• Which of the following is NOT a key goal of ICH E6?
• What is the implication of ICH E6 allowing broader access to confidential medical records?
• When a sponsor transfers responsibilities to a CRO, what must they ensure?
• What is the primary focus of the ICH E6 Section 5?
• What should an investigator include in the consent forms for studies involving illiterate persons?
• What does data integrity refer to in clinical trials?
• In which document must the sponsor outline their commitment to ensuring GCP compliance?
• According to ICH E6, what should be included in the informed consent document?
• What does the sponsor's oversight of CRF data ensure according to ICH?
• What statistical considerations must be made in protocol development?
• What is the significance of data sharing after a clinical trial?
• What does ICH E6 Section 4.3.3 recommend regarding the subject's primary physician?
• Which statement is accurate about the investigator's compliance with ICH regulations?
• What is the underlying purpose of ICH E6?
• Under FDA regulations, how can documentation of informed consent be completed for illiterate subjects?
• Why is it important for investigators to have adequate resources?
• When is the ICH E6 guideline legally enforced?
• According to ICH requirements, who should sign the written informed consent form in case of subjects with cognitive impairments?
• What action must the sponsor take if noncompliance is identified according to ICH E6?
• How many main categories are there in the ICH guidelines?
• The ICH E6 guideline is primarily related to:
• Which aspect of source data is emphasized in ICH E6 Section 4.9.0?
• What measures should be taken in the event of protocol deviations?
• Who is primarily responsible for initiating and conducting a clinical trial?
• According to ICH E6 Section 5.5.3, what does the sponsor need to ensure about electronic trial data handling?
• According to ICH guidelines, when should the investigator ensure that a subject's primary physician is informed?
• Which of the following statements about confidentiality of medical records is true according to ICH E6?
• In the U.S., compliance with the ICH E6 guideline is regarded as:
• What should be documented if a participant withdraws from a clinical trial?
• If noncompliance significantly affects trial results, what action should the sponsor take according to ICH E6?
• In ICH E6, protecting participant rights is considered?
• What does Good Clinical Practice (GCP) primarily enhance?
• What is the goal of the post-study evaluation in a clinical trial?
• Why is ongoing communication important during a clinical trial?
• What is the goal of ICH E6 in implementing a risk-based approach to quality management?
• What is a primary difference between ICH guidelines and FDA regulations regarding investigator's responsibilities?
• What is the role of patients or participants in shaping clinical trial design according to ICH E6?
• What constitutes a serious adverse event (SAE)?
• How long must IRB records be retained after the completion of a trial according to ICH and FDA?
• What circumstances allow for exceptions to the requirement for informed consent under FDA regulations?
• One advantage of complying with ICH E6 is that it helps meet regulatory requirements of which aspect?
• Why is the description of each study arm important in the consent form?
• Which statement accurately describes the rights conferred by the ICH E6 guideline?
• What is a key benefit of ensuring good documentation during a clinical trial?
• What is the sponsor required to ensure regarding the trial according to ICH E6?
• What defines a Protocol Deviation in clinical research?
• What is the Declaration of Helsinki most closely associated with?
• What is necessary for implementing changes to the clinical trial protocol?
• According to ICH E6, what must IRBs obtain for the approval of the trial?
• What is true regarding the initial model for the ICH E6 guideline?
• What is required in the documentation of adverse events during a clinical trial according to ICH E6?
• What does the sponsor's responsibility include concerning trial design?
• How should changes to the clinical trial protocol be handled?
• Which of the following accurately describes the legally binding nature of the ICH E6 guideline in the U.S.?
• What must the investigator obtain to ensure compliance with ICH guidelines?
• What is the significance of the Informed Consent process in clinical trials according to ICH E6?
• According to ICH GCP, where do the ethical principles stem from?
• Which is an essential component of the informed consent form as per ICH recommendations?
• What is the primary purpose of the ICH E6 Guideline?
• In the event of serious noncompliance, what action does ICH E6 recommend regarding an investigator's participation?
• Why might an ICH impartial witness be required during the consent process?
• What is a key aspect of the required components within the ICH E6 guideline?
• How is an "impartial witness" defined in the ICH guidelines?
• How is the role of the Sponsor defined in ICH E6?
• True or False: ICH guidelines have the force of law in the U.S.
• Which section addresses the common practice regarding prorated payment for subjects?
• What type of trials does ICH E6 Section 4.8.13 refer to?
• How long must study-related records be maintained after drug approval in the U.S. according to ICH E6?
• What types of records must be kept by the sponsor as stipulated in ICH E6?
• According to FDA regulations, what signature is required on the informed consent form?
• What must sponsors ensure when delegating responsibilities to a contract research organization (CRO)?
• What should subjects or legally acceptable representatives receive according to ICH guidelines?
• What is the required maintenance period for device investigation records according to FDA regulations?
• According to record-keeping requirements, what must be done if no application is filed for a drug?
• What is an essential requirement for the sponsor according to ICH E6 Section 5.18.3?
• What documentation must an investigator provide to the IRB according to ICH?
• What responsibility does ICH E6 place on the sponsor regarding the research monitoring?
• What aspects of trial reporting are emphasized in ICH E6?
• What approach should the sponsor develop according to ICH E6 for monitoring clinical trials?
• Which statement is true regarding ICH E6 Section 5.5 and FDA regulations?
• True or False: ICH E6 states that the investigator should maintain control of essential documents during and after the trial.
• How does ICH E6 address sponsor responsibilities compared to FDA regulations?
• What does "good documentation" entail in the context of ICH E6?
• What is the minimum record retention time required after the completion of an investigation?
• What information is NOT required by ICH E6 in relation to changes to a research protocol?
• What does ICH E6 require regarding the assent of children in clinical trials?
• What are “Essential Documents” according to ICH E6?